Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
Yale Cancer Center/Smilow Cancer HospitalThe final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.